Organogenesis Holdings Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
ORGO$0.94+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(amounts in thousands, except share and per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue: | ||
| Net product revenue | $36,250 | $86,693 |
| Grant income | 978 | — |
| Total revenue | 37,228 | 86,693 |
| Operating expenses: | ||
| Cost of goods sold | 25,772 | 23,723 |
| Selling, general and administrative | 65,186 | 72,509 |
| Research and development | 15,161 | 10,640 |
| Write-down to fair value for asset held for sale | — | 6,567 |
| Total operating expenses | 106,119 | 113,439 |
| Loss from operations | (68,891) | (26,746) |
| Other income, net: | ||
| Interest income, net | 380 | 961 |
| Other income, net | 38 | 2 |
| Total other income, net | 418 | 963 |
| Net loss before income taxes | (68,473) | (25,783) |
| Income tax benefit | 15,317 | 6,940 |
| Net loss and comprehensive loss | (53,156) | (18,843) |
| Accretion of redeemable convertible preferred stock to redemption value | (159) | (121) |
| Cumulative dividend on redeemable convertible preferred stock | (2,844) | (2,627) |
| Net loss attributable to common stockholders | $(56,159) | $(21,591) |
| Net loss, per share: | ||
| Basic and diluted | $(0.44) | $(0.17) |
| Weighted-average common shares outstanding | ||
| Basic and diluted | 127,797,013 | 126,295,642 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.